Purchase Order 75N91019P00680
Award Date 9/1/19
Potential Completion Date 8/31/21
Potential Value $174K
Federal Agency
Awardee
Ultimate Awardee
Not listed Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed under SAP
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
San Diego, CA 92122, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This is a firm fixed price purchase order awarded by the National Cancer Institute, a civilian agency within the U.S. Department of Health and Human Services, to Illumina, Inc., a for-profit manufacturer of genomic sequencing and analysis equipment. The contract provides for an equipment maintenance agreement on Illumina sequencing systems, such as NextSeq, NovaSeq, MiSeq, and iSeq models, with a ceiling value of $16,198.00 and a performance period ending on December 4, 2025. The contract does...
- This is a $28,749.60 firm-fixed-price delivery order contract awarded by the National Cancer Institute (NCI) to Illumina, Inc., a manufacturer of sequencing and array-based genomic analysis solutions. The contract is for the provision of laboratory equipment and supplies, with no set-aside designation. Through this award, Illumina will provide the NCI with a range of its NextSeq, NovaSeq, MiSeq, and iSeq sequencing systems, as well as accompanying reagents, consumables, sample prep kits,...
- This firm fixed-price purchase order was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to Illumina, Inc. for a one-year comprehensive plan to provide HiSeq 2000, cBOT, and MiSeq systems. The $100,884 contract does not include a set-aside provision. Illumina is a manufacturer of genetic sequencing and analysis instruments and reagents that have been utilized across various federal agencies, including the Centers...
- This is a firm fixed price delivery order contract awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to Illumina, Inc., a manufacturer of sequencing and genomic analysis instruments and reagents. The $13,438.88 contract is for the provision of Illumina's NextSeq, NovaSeq, MiSeq, and iSeq sequencing systems, along with related consumables, support services, and bioinformatics products to support genomic research and diagnostics projects at the...
- This is a $142,990 firm fixed price purchase order contract awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to Illumina, Inc., a manufacturer of genomic sequencing systems and analytical instruments. The contract has no set-aside designation. Illumina has previously received prime federal contract awards from other agencies like the CDC, USDA, and VA to provide sequencing systems, reagents, and related services in support of genomics...
- This is a firm fixed price purchase order contract awarded by the National Cancer Institute (NCI), which is part of the National Institutes of Health (NIH), a civilian federal agency. The contract provides for maintenance services over a 5-year period for an Illumina MiSeq and NextSeq 500 sequencing instruments, which are used to support genomic research at the NCI's Laboratory of Biochemistry and Molecular Biology. The contract has a ceiling value of $250,122.52 and was awarded to Illumina,...
- This is a firm fixed price purchase order contract awarded by the National Cancer Institute (NCI), a civilian agency, to Illumina, Inc., a for-profit manufacturer of genomics sequencing and analysis solutions. The contract, valued at $15,388.08, is for the provision of sequencing systems, reagents, and services to support genomic research and diagnostics. Illumina has a history of providing similar products and services to various federal agencies, including the NIH, CDC, USDA, and VA, under...
- This is a firm fixed price purchase order awarded by the National Cancer Institute (NCI), a civilian agency under the Department of Health and Human Services (HHS), to Illumina, Inc. for maintenance services on Illumina HiScan, MiSeq, and cBot equipment. The contract has a ceiling value of $112,799.09 and runs through March 8, 2023. There is no set-aside designation for this award. Through past prime federal contracts, Illumina has provided sequencing systems, reagents, and other products and...
- This firm fixed-price purchase order was awarded by the Department of Health and Human Services' National Institutes of Health National Cancer Institute to Illumina, Inc., a manufacturer of genetic sequencing systems and solutions, for preventive maintenance, emergency service, and support for a government-owned Illumina NovaSeq 6000 Sequencing System. The contract has a period of performance from August 1, 2022 to July 31, 2023 and a potential value of $119,523.28. The requirement was...
- This is a $15,388.08 firm fixed-price purchase order awarded by the National Cancer Institute (NCI), a civilian federal agency, to Illumina, Inc., a for-profit manufacturer of genomic sequencing and analysis products. The contract is for a service agreement for a MiSeq M05802 sequencing system, with a completion date of December 7, 2025. Illumina has previously received prime contracts and subcontracts from various federal agencies, including the NIH, CDC, USDA, and VA, to provide sequencing...